Drug Markets/Galcanezumab-Gnlm

Galcanezumab-Gnlm

3 NDCs across 1 manufacturer|0 Generic,3 Brand

Galcanezumab-Gnlm is used to treat cluster headache, per the National Library of Medicine's MED-RT classification.

▸ More about this market

In 2024, Medicare Part D spent $305 million on Galcanezumab-Gnlm across 349,000 claims for 61,000 beneficiaries.

Galcanezumab-Gnlm is available as 3 NDCs from 1 manufacturer (0 generic, 3 brand), with NADAC prices from $612.59 to $734.53 per MLa 20% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.

Total NDCs

3

0G / 3B

Manufacturers

1

competing in market

Price Spread

$612.59 – $734.53

per ML

7d Activity

20 flat

avg +0.0% WoW · of 3 NDCs

Market Price Trend

Monthly average NADAC per unit, split by generic and brand.

Manufacturer Breakdown

1 manufacturer producing GALCANEZUMAB-GNLM

Drug Portfolio

3 NDCs total, 3 shown

Drug Price 7d Change
EMGALITY 120 MG/ML SYRINGE
$734.5303
per ML
+0.06%
EMGALITY 120 MG/ML PEN
$734.2237
per ML
0.00%
EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES)
$612.5901
per ML
+0.02%

Frequently Asked Questions

What is Galcanezumab-Gnlm used to treat?

Galcanezumab-Gnlm is used to treat cluster headache, per the National Library of Medicine's MED-RT classification.

How much does Medicare spend on Galcanezumab-Gnlm?

In 2024, Medicare Part D spent $305 million on Galcanezumab-Gnlm across 349,000 claims for 61,000 beneficiaries.

How many Galcanezumab-Gnlm products are on the market?

The Galcanezumab-Gnlm drug market contains 3 NDCs from 1 manufacturer — 0 generic and 3 brand products.

What is the price range for Galcanezumab-Gnlm?

NADAC reference prices for Galcanezumab-Gnlm range from $612.5901 to $734.5303 per ML — a 20% difference between cheapest and most expensive.

Which manufacturers make Galcanezumab-Gnlm?

1 manufacturer lists Galcanezumab-Gnlm in NADAC. Ranked by number of NDCs, the largest are Eli Lilly and Company (3).

How has the price of Galcanezumab-Gnlm changed recently?

Over the past 7 days, 2 Galcanezumab-Gnlm NDCs rose and 0 fell, with a market-wide average change of +0.0%.